125.07 0.00 (0.00%)
After hours: 4:16PM EDT
|Bid||125.47 x 1100|
|Ask||140.16 x 800|
|Day's Range||124.62 - 129.46|
|52 Week Range||103.00 - 149.07|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||28.19|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||152.79|
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs. Swiss biotech Lonza and U.S.-based Charles River Laboratories are the biggest suppliers of crab blood-based endotoxin tests, which detect bacterial contamination in intravenous drugs and medical implants. Meanwhile Charles River, which is still studying rFC, argues moving too quickly could compromise patient safety.
If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs. Every year, fishermen net hundreds of thousands of the creatures off the U.S. East Coast and in Asia before their prized milky-blue blood is drained for use in medical safety tests. Swiss biotech Lonza and U.S.-based Charles River Laboratories are the biggest suppliers of crab blood-based endotoxin tests, which detect bacterial contamination in intravenous drugs and medical implants.
Charles River (CRL) delivered earnings and revenue surprises of 5.16% and -0.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
James Foster became the CEO of Charles River Laboratories International, Inc. (NYSE:CRL) in 1992. This report will...
Charles River Laboratories International, Inc. will release second-quarter 2019 financial results on Wednesday, July 31st, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, July 31st, at 8:30 a.m.
Charles River Laboratories International, Inc. (CRL) today announced the planned opening of the Charles River Accelerator and Development Lab (CRADL™) in South San Francisco in early 2020. CRADL provides flexible, turnkey vivarium rental space supported by Charles River’s technical, vivarium, and veterinary support expertise in key biohubs. CRADL is the leading space for clients to launch or expand their drug research programs, with the added benefit of access to Charles River’s complete portfolio of integrated drug discovery resources.
Does Charles River Laboratories International Inc. (NYSE:CRL) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why […]
During the Lightning Round of Mad Money Thursday night, Jim Cramer mentioned to one caller that he also likes Charles River Laboratories International Inc. In the daily bar chart of CRL, below, we can see some bearish signals. The On-Balance-Volume (OBV) line shows weakness from late April telling us that sellers of CRL have become more aggressive.
Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CRL totaled $7 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Charles River Laboratories International, Inc. announced today that it will present at two upcoming investor conferences, including:
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Charles River earnings of $1.40 a share, on an adjusted basis, on $604.6 million in sales beat first-quarter estimates Tuesday. But shares closed down on worries of a China trade war.
Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Wilmington, Massachusetts-based company said it had profit of $1.11 per share. Earnings, adjusted for non-recurring costs, came to $1.40 per share. The results surpassed Wall Street expectations. The ...